Researchers have evaluated a simple blood test measuring plasma p-tau217 in nearly 600 Latin Americans across six countries, adding large-scale evidence that a potentially lower-cost screening tool can help detect Alzheimer’s-related pathology in a population long excluded from Alzheimer’s research. The study, conducted through the ReDLat consortium spanning Chile, Argentina, Colombia, Peru, Mexico, and Brazil, measured the biomarker on an automated platform used in an FDA-cleared Alzheimer’s blood test. The findings arrive as scientists separately report that p-tau217-based models may help estimate when Alzheimer’s symptoms are likely to begin, underscoring the stakes for equitable access to biomarker testing across the Americas.
Why Latin Americans Have Been Left Out
Latin America is home to one of the fastest-growing older adult populations on the planet, yet dementia research has overwhelmingly relied on cohorts of European descent. That gap matters because genetic ancestry, environmental exposures, and comorbidity profiles can all shift how biomarkers perform in different groups. A test validated primarily in North American or European patients may produce misleading results when applied to populations with distinct admixture patterns, potentially delaying diagnosis for the people who need it most.
UC San Diego researchers involved in the ReDLat work have been blunt about the problem. “Despite this, they’re still significantly underrepresented in Alzheimer’s and dementia research, which is something our study aims to address,” the UC San Diego report noted in a recent institutional report. That underrepresentation is not just an academic blind spot. It means clinicians in Santiago, Lima, or Sao Paulo have had limited evidence to guide whether blood-based biomarkers work reliably for their patients, leaving diagnosis dependent on expensive PET scans or invasive cerebrospinal fluid draws that many regional hospitals cannot offer.
How the Blood Test Performed Across Six Countries
The ReDLat validation study enrolled approximately 600 participants from Chile, Argentina, Colombia, Peru, Mexico, and Brazil, measuring plasma p-tau217 from EDTA plasma samples on the Lumipulse G600II automated platform. That platform choice is significant: it is the same Lumipulse system used for the Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio test that the FDA cleared for diagnosing Alzheimer’s in cognitively impaired adults, based on multicenter clinical data from 499 plasma samples. Because the work used the same instrument platform, the Latin American results can be more readily compared with published performance data that supported U.S. clearance of the related Lumipulse plasma ratio test.
A separate longitudinal study from Brazil reinforced those findings with tighter numbers. In a cohort of 145 participants followed for up to 4.7 years, plasma p-tau217 achieved an area under the curve of approximately 0.94 for matching cerebrospinal fluid biomarker status, a strong indicator of diagnostic accuracy. When researchers combined p-tau217 with the amyloid-beta 42 ratio, the AUC climbed to approximately 0.98, a level of precision that rivals gold-standard spinal fluid analysis. These metrics suggest the blood draw could replace far more invasive and costly procedures for initial screening in resource-limited settings.
Platform Precision and Real-World Reliability
A blood test is only useful if it delivers consistent results across different labs and clinical environments. Head-to-head technical comparisons published in Brain evaluated the Lumipulse automated platform against the SIMOA/ALZpath system, reporting precision and repeatability metrics including control coefficients of variation. The Lumipulse system demonstrated clear group separations between Alzheimer’s patients, healthy controls, and individuals with non-Alzheimer’s neurodegenerative disorders. That three-way discrimination is important because misclassifying frontotemporal dementia or Lewy body disease as Alzheimer’s can lead to inappropriate treatment plans.
Additional memory-clinic data from a cohort of approximately 493 patients confirmed the Lumipulse G600II platform’s diagnostic performance when benchmarked against cerebrospinal fluid biomarkers. Taken together, these technical validations give clinicians in Latin America a reason to trust that the same automated assay performing well in U.S. and European settings can hold up under real-world conditions in their own hospitals. The practical benefit is direct: a single blood draw processed on standardized equipment could replace the need for a lumbar puncture or a PET scan costing thousands of dollars.
From Diagnosis to Prediction
Identifying Alzheimer’s pathology in someone already showing cognitive decline is valuable, but the larger promise of p-tau217 lies in forecasting who will develop symptoms years before they appear. Scientists have reported a blood-test approach that may help estimate when Alzheimer’s symptoms are likely to begin by measuring plasma p-tau217 and building predictive “clocks” from baseline levels, according to research published in Nature Medicine. That study used baseline plasma p-tau217-derived models to calculate time-to-symptomatic onset in a well-characterized cohort, moving the conversation from reactive diagnosis toward proactive risk management.
For Latin American health systems, this predictive capacity could reshape how limited resources are allocated. If a primary care physician in rural Colombia or a public hospital in Buenos Aires can draw blood, ship it to a regional lab, and receive biomarker results that suggest elevated Alzheimer’s-related pathology risk, they could prioritize follow-up evaluation, cognitive monitoring, and planning for future access to therapies for those most likely to benefit. Researchers rely on platforms such as the National Center for Biotechnology Information to track emerging biomarker data, and tools like MyNCBI dashboards and curated bibliography collections are helping teams across the region stay aligned on evolving evidence as they design predictive algorithms tailored to local populations.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
